WHO Endorses Gilead's Biannual HIV Prevention Injection for Global Rollout
TL;DR
WHO recommends offering long-acting injectable lenacapavir (LEN) as an additional HIV prevention option, administered twice a year, to increase PrEP uptake and effectiveness. The guideline emphasizes using rapid diagnostic tests for individuals on injectable PrEP like LEN and cabotegravir, promoting flexible testing approaches to ensure access and continuation of PrEP, and highlights the need for further research, including HIV self-testing for long-acting injectable PrEP.
- Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis World Health Organization (WHO)
- WHO recommends twice-a-year HIV prevention shot as concern looms over funding for global HIV fight CNN
- WHO recommends Gilead's twice-yearly injection for HIV prevention Reuters
- Gilead to provide HIV prevention drug to 2 million people in lower-income countries at cost STAT
- WHO urges rollout of first long-acting HIV prevention jab UN News
Want the full story? Read the original reporting
Read on World Health Organization (WHO)